Wilmington, Delaware, United States, Transparency Market Research. Inc. , July 08, 2024 (GLOBE NEWSWIRE) -- The prostate health market (Markt für Prostatagesundheit) was projected to attain US$ 31.9 billion in 2023. It is likely to garner a 9.2% CAGR from 2024 to 2034, and by 2034, the market is expected to attain US$ 83.8 billion.
Higher spending on healthcare, especially in emerging economies, is supporting the growth of the prostate health market. Improved access to healthcare services is another contributing factor. The trend towards personalized medicine, including genetic testing and tailored treatment plans, is gaining traction in the prostate health market.
The shift towards non-invasive or minimally invasive treatment options, such as robotic-assisted surgeries and laser therapies, is becoming more prevalent. AI and machine learning are increasingly being integrated into diagnostic and treatment processes, improving accuracy and outcomes.
Request a PDF Sample of this Report Now!
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=84727
The adoption of telemedicine and digital health platforms is facilitating remote consultations and monitoring, making prostate health services more accessible. There is a growing interest in nutraceuticals and dietary supplements aimed at promoting prostate health, driven by the preference for natural and preventive approaches.
Continued investment in R&D for innovative treatments, including new drug formulations and advanced surgical techniques, presents opportunities for market players. Increasing emphasis on preventive healthcare and early diagnosis offers opportunities for companies providing screening tools and preventive treatments.
The prostate health market is growing due to rising cases of diseases like benign prostatic hyperplasia (BPH) and prostate cancer. Globally, there were 1,414,259 new prostate cancer cases in 2020, with North America and Europe leading at 73.7% and 62.1%, respectively, while Africa and Asia had lower rates at 26.6% and 11.5%. Age-related BPH prevalence is significant, affecting about 50% of men aged 51-60 and up to 90% of those over 80.
Advancements in treatments, such as Novartis' 177Lu-PSMA-617, which improved survival rates in metastatic castration-resistant prostate cancer, and early diagnosis campaigns are further driving market growth.
Key Findings of the 전립선 건강 Market Report
- Ongoing research into biomarkers for prostate diseases is improving the accuracy of diagnostics and enabling earlier detection of prostate conditions.
- A shift towards patient-centric care models, which focus on individualized treatment plans and patient engagement, is gaining momentum.
- There is a growing interest in holistic and integrative approaches to prostate health, combining conventional treatments with complementary therapies such as acupuncture, herbal medicine, and yoga.
- The use of big data and analytics in healthcare is helping to identify trends, improve diagnostic accuracy, and develop more effective treatment protocols for prostate health.
Market Trends for Prostate Health (前立腺の健康)
- By disease type, the prostate cancer segment is anticipated to augment the growth of the prostate health market.
- Adenocarcinoma is the most common type of prostate cancer, accounting for the majority of prostate cancer cases. The high prevalence and incidence rates significantly drive the demand for diagnostic and therapeutic solutions.
- Innovations in diagnostic techniques, such as prostate-specific antigen (PSA) testing, MRI fusion biopsies, and advanced imaging technologies, have improved early detection and diagnosis rates.
- In terms of treatment, the hormone therapy segment is expected to propel the market growth.
- Hormone therapy is particularly effective in managing advanced stages of prostate cancer, including metastatic and recurrent cases, by reducing or blocking the production of androgens, which fuel prostate cancer growth.
Global Market for Prostate Health: Regional Outlook
North America
- North America has one of the highest incidences of prostate diseases, particularly prostate cancer and benign prostatic hyperplasia (BPH).
- This high prevalence drives demand for diagnostic tests, treatments, and supportive care services.
- North America boasts advanced healthcare infrastructure with access to state-of-the-art diagnostic tools, treatment options, and specialized healthcare providers.
- This infrastructure supports early detection, diagnosis, and treatment of prostate diseases, enhancing patient outcomes.
Asia Pacific
- Rapid advancements in medical technology and healthcare delivery systems are transforming prostate health management in Asia Pacific.
- This includes the adoption of robotic surgery for prostatectomies, advanced imaging techniques for early detection, and telemedicine solutions for remote patient monitoring and consultations.
- There is a growing emphasis on healthcare awareness and preventive screening programs for prostate diseases in Asia Pacific.
- Public health initiatives, educational campaigns, and screening drives increase early detection rates and promote timely medical intervention.
Unlock Growth Potential in Your Industry! Download PDF Brochure: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=84727
Prostate Health Market: Key Players
The competitive landscape of the prostate health market is dynamic and multifaceted, characterized by a range of players including pharmaceutical companies, biotechnology firms, medical device manufacturers, and dietary supplement producers. The following companies are well known participants in the prostate health market:
- Abbott Laboratories
- Amgen Inc.
- Astellas Pharma Inc.
- AstraZeneca PLC
- Bayer AG
- Bristol-Myers Squibb (BMS)
- Eli Lilly and Company
- Ferring Pharmaceuticals
- GSK PLC.
- Johnson & Johnson
- Merck and Co. Inc.
- Pfizer Inc.
- Siemens Healthineers AG
Key Developments
- In 2022, Teleflex introduced the UroLift System in India to address benign prostatic hyperplasia (BPH) or enlarged prostate. This system offers a minimally invasive treatment option for BPH, enabling the procedure to be performed as a same-day outpatient service.
- In the same year, Novartis obtained approval from the European Commission (EC) for Pluvicto (lutetium (177Lu) vipivotide tetraxetan), a targeted radioligand therapy. It is indicated for treating adult patients with metastatic castration-resistant prostate cancer (mCRPC) who are positive for prostate-specific membrane antigen (PSMA).
Prostate Health (Salute della prostata) Market Segmentation
Disease Type
- Prostatitis
- Benign Prostatic Hyperplasia (BPH)
- Prostate Cancer
- Adenocarcinoma
- Transitional Cell Carcinoma
- Squamous Cell Carcinoma
- Small Cell Prostate Cancer
Treatment
- Chemotherapy
- Hormone Therapy
- Immunotherapy
Route of Administration
- Oral
- Parenteral
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Region
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa
Buy this Premium Research Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=84727<ype=S
More Trending Reports by Transparency Market Research –
Women's Health Market - The global marché de la santé des femmes is projected to advance at a CAGR of 5.5% from 2023 to 2031
Home Healthcare Market - The global mercado de atención médica domiciliaria is projected to expand at a CAGR of 10.5% during the forecast period from 2021 to 2028
About Transparency Market Research
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact:
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Email: sales@transparencymarketresearch.com
Follow Us: LinkedIn| Twitter| Blog | YouTube
